Ustekinumab is a monoclonal antibody directed against the p40 subunit, which is 
part of interleukins IL-12 and IL-23. The efficacy of ustekinumab versus placebo 
in terms of clinical response and remission of induction has been shown in 
phase3 clinical trials. When used as subcutaneous maintenance therapy, the 
therapeutic benefit of ustekinumab over placebo has been confirmed in both 
clinical response and remission in patients who have responded clinically to 
induction therapy. In addition, ustekinumab has demonstrated an improvement in 
mucosal healing parameters. The safety profile of the drug has been good, with 
low infection rates (without reactivation of tuberculosis) and absence of tumour 
reporting. The development of drug immunogenicity appears to be rare. In 
summary, ustekinumab is a promising treatment option in patients with Crohn's 
disease, as an alternative to anti-TNFα drugs.